MoveSurge Every market-moving story. Fast. Clear. Complete.

Sign In Start Pro — $29 for 7 days$29 Pro

Never miss the news that moves markets. Every market-moving story. Fast. Clear. Complete. Wide coverage Global markets and U.S. stocks of every size. Fast Important news reaches you as it breaks. Clear Plain words and extra context only when you need it.

Analyst-led coverage since 2006 Covers: Global markets, all sizes of U.S. stocks, central banks, economic data, politics, oil, gold, and more. Direct sources included

Insights › Stocks

Replimune Group (REPL) News Today

Every REPL headline we timestamp, with the price move measured one minute and fifteen minutes after it crossed the tape.

Our analysis

The FDA Just Approved the First Cancer Virus Therapy Paired With a Checkpoint Inhibitor — and Replimune Made It

The FDA granted accelerated approval to Replimune's oncolytic virus therapy, TUDRIQEV, in combination with the checkpoint inhibitor nivolumab, for adults with advanced melanoma that progressed on …

Why Is Replimune (REPL) Stock Moving Today?

Replimune is a clinical-stage biotech developing oncolytic virus therapies for cancer. This page tracks what's actually moving the stock — FDA decisions, analyst calls, and trial …

Related coverage

The next market-moving story will not wait

See the important story while it still matters.

Seven market specialists bring experience dating back to 2006. MoveSurge adds the speed, coverage, and clear format built for today’s market.

Wide coverageGlobal markets and every size of U.S. stock Clear in secondsThe story, source, context, and measured move together Built on evidenceReal headlines, timestamps, prices, and trusted sources

Start Pro — $29 for 7 days View the live feed $29 today for 7 days. Then renews at the selected plan unless cancelled. Information only—no trade calls.